Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Lowered to Buy at Vetr Inc.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was downgraded by research analysts at Vetr from a “strong-buy” rating to a “buy” rating in a note issued to investors on Monday, July 31st. They currently have a $6.74 price objective on the biotechnology company’s stock. Vetr‘s target price points to a potential upside of 11.40% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. FBR & Co set a $11.00 price target on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, April 8th. HC Wainwright dropped their price target on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, May 18th. Cantor Fitzgerald restated a “buy” rating and issued a $14.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, April 21st. BidaskClub cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Zacks Investment Research cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $9.28.

Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) traded up 5.95% on Monday, hitting $6.05. The stock had a trading volume of 1,287,699 shares. The stock has a 50 day moving average price of $6.34 and a 200-day moving average price of $6.16. Aurinia Pharmaceuticals has a 12-month low of $1.74 and a 12-month high of $10.54. The company’s market cap is $503.80 million.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The business had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 38.20% and a negative net margin of 16,648.93%. On average, equities analysts expect that Aurinia Pharmaceuticals will post ($0.74) earnings per share for the current year.

WARNING: “Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Lowered to Buy at Vetr Inc.” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://stocknewstimes.com/2017/08/12/aurinia-pharmaceuticals-inc-nasdaqauph-cut-to-buy-at-vetr-inc-updated.html.

A number of institutional investors have recently added to or reduced their stakes in the company. AWM Investment Company Inc. acquired a new position in Aurinia Pharmaceuticals during the first quarter valued at about $2,202,000. Morgan Stanley boosted its position in Aurinia Pharmaceuticals by 11,061.7% in the first quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock valued at $3,273,000 after buying an additional 442,138 shares during the last quarter. UBS Group AG boosted its position in Aurinia Pharmaceuticals by 13.6% in the first quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock valued at $824,000 after buying an additional 13,405 shares during the last quarter. Monashee Investment Management LLC acquired a new position in Aurinia Pharmaceuticals during the first quarter valued at about $1,835,000. Finally, FMR LLC acquired a new position in Aurinia Pharmaceuticals during the first quarter valued at about $42,928,000. Institutional investors own 29.48% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply